Antigen Presenting Cells in the Induction of GVHD

抗原呈递细胞在 GVHD 诱导中的作用

基本信息

  • 批准号:
    7354061
  • 负责人:
  • 金额:
    $ 23.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-03-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goals of this research program are to understand the molecular and cellular basis of graft-versus-host disease (GVHD), and to use this understanding to prevent the toxicity and mortality caused by GVHD. This application takes advantage of mouse models of human stem cell transplantion, in which we have shown that host antigen presenting cells (APCs) rapidly prime antigen-specific donor T cells that will later go on to cause phenotypic GVHD. Moreover, we have new evidence that APC-T cell activation is a multi-step process, which may allow decisive intervention by targeting each of these activation steps. To most directly explore and exploit these findings, we propose to investigate: 1) The relative contributions of distinct APC subsets (dendritic cells, macrophages, B cells, and activated endothelial cells), and of host- versus donor-derived APCs, to initiating GVHD; 2) The immunoregulatory signals by which APCs stimuate allogeneic T cell survival essential for subsequent T cell activation, proliferation and differentiation in vivo; and 3) Whether ex vivo selection of host miHA-acivated donor CD44hiCD8+ T cells, or in vivo blockade of APC-donor T cell linteractions, can effectively prevent GVHD. These studies will establish the preclinical basis for therapeutic approaches targeting APCs for the prevention of GVHD. Based upon the results of these studies, our long-term goal is to develop the appropriate reagents to target human APCs, including DCs and macrophages, at the cellular and/or molecular levels, to prevent GVHD in clinical trials.
描述(由申请人提供):该研究项目的目标是了解移植物抗宿主病(GVHD)的分子和细胞基础,并利用这种理解来预防 GVHD 引起的毒性和死亡。该应用利用了人类干细胞移植的小鼠模型,在该模型中,我们证明宿主抗原呈递细胞 (APC) 会快速启动抗原特异性供体 T 细胞,这些细胞随后会导致表型 GVHD。此外,我们有新的证据表明 APC-T 细胞激活是一个多步骤过程,这可能允许通过针对每个激活步骤进行决定性干预。为了最直接地探索和利用这些发现,我们建议研究:1)不同的 APC 亚群(树突状细胞、巨噬细胞、B 细胞和活化的内皮细胞)以及宿主与供体来源的 APC 对引发 GVHD 的相对贡献; 2) APC 刺激同种异体 T 细胞存活的免疫调节信号,这对于随后的体内 T 细胞激活、增殖和分化至关重要; 3)无论是体外选择宿主miHA激活的供体CD44hiCD8+T细胞,还是体内阻断APC-供体T细胞相互作用,都可以有效预防GVHD。这些研究将为针对 APC 预防 GVHD 的治疗方法奠定临床前基础。根据这些研究的结果,我们的长期目标是开发合适的试剂,在细胞和/或分子水平上靶向人类APC,包括DC和巨噬细胞,以预防临床试验中的GVHD。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Notch and inflammatory T-cell response: new developments and challenges.
  • DOI:
    10.2217/imt.11.126
  • 发表时间:
    2011-11
  • 期刊:
  • 影响因子:
    2.8
  • 作者:
    Mochizuki K;He S;Zhang Y
  • 通讯作者:
    Zhang Y
Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
  • DOI:
    10.1016/j.bbmt.2010.01.012
  • 发表时间:
    2010-06
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Kato, Koji;Cui, Shuaiying;Kuick, Rork;Mineishi, Shin;Hexner, Elizabeth;Ferrara, James L. M.;Emerson, Stephen G.;Zhang, Yi
  • 通讯作者:
    Zhang, Yi
CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease.
由供体造血干细胞从头产生的 CD4 T 细胞介导从急性到慢性移植物抗宿主病的演变。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YI ZHANG其他文献

YI ZHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YI ZHANG', 18)}}的其他基金

DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity
DOT1L,浆细胞样树突状细胞和同种免疫的重建
  • 批准号:
    10531377
  • 财政年份:
    2021
  • 资助金额:
    $ 23.47万
  • 项目类别:
DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity
DOT1L,浆细胞样树突状细胞和同种免疫的重建
  • 批准号:
    10582730
  • 财政年份:
    2021
  • 资助金额:
    $ 23.47万
  • 项目类别:
Ezh2-mediated Epigenetic Effects and Alloimmunity
Ezh2介导的表观遗传效应和同种免疫
  • 批准号:
    9028856
  • 财政年份:
    2016
  • 资助金额:
    $ 23.47万
  • 项目类别:
Ezh2-mediated Epigenetic Effects and Alloimmunity
Ezh2介导的表观遗传效应和同种免疫
  • 批准号:
    9198995
  • 财政年份:
    2016
  • 资助金额:
    $ 23.47万
  • 项目类别:
Delta-like ligand 4+ dendritic cells and induction of alloimmunity
Delta样配体4树突状细胞和同种免疫的诱导
  • 批准号:
    9207071
  • 财政年份:
    2012
  • 资助金额:
    $ 23.47万
  • 项目类别:
Delta-like ligand 4+ dendritic cells and induction of alloimmunity
Delta样配体4树突状细胞与同种免疫的诱导
  • 批准号:
    8787454
  • 财政年份:
    2012
  • 资助金额:
    $ 23.47万
  • 项目类别:
Delta-like ligand 4+ dendritic cells and induction of alloimmunity
Delta样配体4树突状细胞与同种免疫的诱导
  • 批准号:
    8416792
  • 财政年份:
    2012
  • 资助金额:
    $ 23.47万
  • 项目类别:
Delta-like ligand 4+ dendritic cells and induction of alloimmunity
Delta样配体4树突状细胞与同种免疫的诱导
  • 批准号:
    8826406
  • 财政年份:
    2012
  • 资助金额:
    $ 23.47万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 23.47万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了